Dr. Zafar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8260 Gladiolus Dr
Fort Myers, FL 33908Phone+1 239-437-5755Fax+1 239-437-5776
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2010 - 2013
Wayne State University School of MedicineResidency, Internal Medicine, 2006 - 2010
Dow University of Health SciencesClass of 2003
Certifications & Licensure
FL State Medical License 2013 - 2025
GA State Medical License 2010 - 2025
MI State Medical License 2006 - 2012- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2013-2014
Publications & Presentations
PubMed
- 39 citationsRandomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-...M. Kundranda, A.C. Gracian, S.F. Zafar, E. Meiri, Johanna C. Bendell
Annals of Oncology. 2020-01-01 - 30 citationsZanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single...Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke
The Lancet. Haematology. 2023-01-01 - 56 citationsPleiotropic effects of genistein in metabolic, inflammatory, and malignant diseasesGanji Purnachandra Nagaraju, Syed F. Zafar, Bassel F. El-Rayes
Nutrition Reviews. 2013-08-01
Journal Articles
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerRonan J Kelly 1, Jaffer A Ajani 1, Jaroslaw Kuzdzal 1, Thomas Zander 1, Eric Van Cutsem 1, Guillaume Piessen 1, Guillermo Mendez 1, Josephine Feliciano 1, Satoru Motoy..., N Engl J Med . 2021 Apr 1;384(13):1191-1203, 4/1/2021
- Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-...Kundranda M, Gracian AC, Zafar SF et al, ANN Oncol. 2020 Jan;31(1):79-87. doi: 10.1016/j.annonc.2019.09.004, 1/31/2020
Abstracts/Posters
- Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinibazyar Shadman, MD, MPH1*, Jeff P Sharman, MD2, Moshe Y. Levy, MD3, Jamal Misleh, MD4*, Syed F. Zafar, MD5, Benjamin B. Freeman, MD6*, John M. Burke, MD7, Jennifer L. C..., ASH- Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III Hematology Disease Topics & Pathways, ASH/Blood
- Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymp...ohn G. Gribben, MD, DSc, FRCP, FMedSci, FRCPath1, Wojciech Jurczak, MD, PhD2, Ryan Jacobs, MD3, Sebastian Grosicki, MD, PhD4, Krzysztof Giannopoulos, MD, PhD5, Tomasz ..., American Society of Hematology/ Blood
Press Mentions
Florida Cancer Specialists & Research Institute Expands Care with New Cancer Center Location in Lee CountyMay 18th, 2022- Cancer Health Care Workers in NC Discuss the Best Way to Achieve Equity in Care – and the Answer Could Lie in RaleighNovember 16th, 2021
Health Matters: Colon Cancer Targeting Younger PatientsMarch 26th, 2018- Join now to see all
Grant Support
- Elkin GrantEmory UniversityPresent
Research History
- Clinical Investigator/PIPrincipal Investigator, leading and overseeing efforts for various phase 2 and 3 trials
Professional Memberships
- ASCOMember
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
